Core Viewpoint - The company has entered into a distribution and supply agreement with PT Ferron, a leading pharmaceutical company in Indonesia, for the commercialization of BRIMOCHOL™PF, an innovative drug for treating presbyopia [1] Group 1: Agreement Details - The agreement grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL™PF in Indonesia [1] - The company will receive an upfront payment and may earn additional milestone payments based on specific achievements [1] Group 2: Product Information - BRIMOCHOL™PF is a preservative-free, experimental eye drop administered once daily to correct age-related near vision loss [1] - The drug developer, Tenpoint, announced that the FDA has accepted the new drug application for BRIMOCHOL™PF, with a review deadline set for January 28, 2026 [1] Group 3: Clinical Study - BRIO-II is a three-arm, multi-center, randomized, double-blind study assessing the safety and efficacy of BRIMOCHOL™PF compared to other treatments, involving 629 participants across 47 trial centers in the U.S. [1]
兆科眼科-B(06622.HK)：就于印度尼西亚商业化BRIMOCHOL™PF与PT Ferron订立分销协议